These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Laquinimod in multiple sclerosis.
    Author: Giacomini PS, Bar-Or A.
    Journal: Clin Immunol; 2012 Jan; 142(1):38-43. PubMed ID: 21450529.
    Abstract:
    Laquinimod is a novel, orally administered immune-modulatory molecule in advanced phase clinical trials in relapsing-remitting multiple sclerosis. Experimental evidence to date, derived mostly from animal models of multiple sclerosis, suggests that laquinimod may mediate its effects via modulating pro-inflammatory immune responses and interfering with cell trafficking, as well as potentially acting directly in the central nervous system to limit demyelination and axonal injury. The clinical trial results to date have established efficacy on imaging markers of disease activity and have shown a favorable safety and tolerability profile. If phase III studies confirm clinical efficacy and safety, laquinimod would represent a welcome new option in the treatment of multiple sclerosis.
    [Abstract] [Full Text] [Related] [New Search]